Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study

NCT01879618 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01879618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01879618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
March 31, 2016
Enrollment
152 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure